Profitability and capital efficiency targets for the fiscal year ending March 2023
First written in FY2020-Q3. 8 of 13 entries say "Advanced", first in FY2020. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AchievedAnnual report
「The adjusted operating margin for the current consolidated fiscal year was 20.0%.」
The Company stated that it had achieved 20.0% for the medium- to long-term management strategy milestone of an adjusted operating margin above 20% for the fiscal year ending March 2023. - FY2023-Q3AdvancedAnnual report
「Due to the factors described above, operating income increased by ¥40.341 billion year on year to ¥142.572 billion.」
Against the target of an operating margin above 20% for the fiscal year ending March 2023, the operating margin for continuing operations for the nine months ended FY2023-Q3 was approximately 22.2%, remaining above the target level as of the first half. However, achievement of the full-year target had not been confirmed in this quarterly report. - FY2023-Q2AdvancedAnnual report
「Operating income increased by ¥22.941 billion year on year to ¥93.603 billion.」
For the six months of FY2023-Q2, operating income from continuing operations was ¥93.603 billion and revenue was ¥417.060 billion, resulting in an operating margin of approximately 22.4%, above the target level of 20% or higher for the fiscal year ending March 2023 as of the first half. - FY2023-Q1AdvancedAnnual report
「Due to the factors described above, operating income increased by ¥13.164 billion year on year to ¥40.776 billion.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, the operating margin in FY2023-Q1 was approximately 19.0%, approaching the target level from 17.7% for FY2022 as a whole. - FY2022AdvancedAnnual report
「As a result of executing its management strategy based on this approach, the Company aims to sustain annual revenue growth of 5%–6%, achieve an operating margin above 20%, comparable to global medtech companies, and secure a leading position in the therapeutic areas on which it is focusing.」
The Company reaffirmed its target of an operating margin above 20% for the fiscal year ending March 2023 and explicitly stated targets of annual revenue growth of 5%–6% and securing a leading position in its focus therapeutic areas. The operating margin in FY2022 was 17.7%. - FY2022-Q3AdvancedAnnual report
「Due to the factors described above, operating income increased by ¥44.176 billion year on year to ¥108.910 billion.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, the operating margin for the nine months ended the third quarter improved to approximately 17.3%. It increased from approximately 12.6% in the same period of the previous fiscal year, approaching the target level. - FY2022-Q2AdvancedAnnual report
「Operating income increased by ¥45.964 billion year on year to ¥76.256 billion.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, the first-half operating margin improved to approximately 18.5%, approaching the target level from approximately 9.6% in the first half of the previous fiscal year. - FY2022-Q1AdvancedAnnual report
「(5) Operating income: Due to the factors described above, operating income increased by ¥23.903 billion year on year to ¥27.612 billion.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, operating income in FY2022-Q1 was ¥27.612 billion and the operating margin was approximately 14.4%. This was a significant improvement from the same period of the previous fiscal year, but remained below the target level. - FY2021WorsenedAnnual report
「The operating margin for the current consolidated fiscal year was 11.2%, deteriorating by 1.0 percentage point from the previous fiscal year due to the spread of COVID-19, despite progress in improving SG&A efficiency.」
Against the target of an operating margin above 20% for the fiscal year ending March 2023, the operating margin was 11.2% in FY2021, deteriorating by 1.0 percentage point from the previous fiscal year. - FY2021-Q3WorsenedAnnual report
「Revenue from continuing operations for the group's consolidated nine-month period decreased 8.5% year on year to ¥513.584 billion. Revenue declined in all businesses due to restrictions on promotional activities and other factors resulting from the COVID-19 pandemic. The operating result from continuing operations was ¥64.734 billion, down 23.6% year on year, as the decline in revenue across all businesses outweighed the decrease in selling, general and administrative expenses.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, continuing operations reported lower revenue and profit for the nine months ended the third quarter, and the operating margin remained at approximately 12.6%. - FY2021-Q2WorsenedAnnual report
「Revenue from continuing operations for the six months ended the second quarter of the current consolidated fiscal year declined across all businesses to ¥316.5 billion, down 14.1% year on year, due in part to restrictions on promotional activities resulting from the impact of COVID-19. Operating income from continuing operations was ¥30.292 billion, down 45.7% year on year, as the decline in revenue across all businesses outweighed the decrease in selling, general and administrative expenses.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, continuing operations reported lower revenue and profit in the first half, and the operating margin declined to approximately 9.6%. - FY2020AdvancedAnnual report
「Despite the impact of COVID-19, the operating margin for the current consolidated fiscal year was 10.5%, an improvement of 6.9 percentage points year on year, as a result of more efficient SG&A management.」
Against the target of an operating margin of 20% or higher for the fiscal year ending March 2023, the Company reported a current-period operating margin of 10.5%, an improvement of 6.9 percentage points year on year. - FY2020-Q3First statedAnnual report
「The Company has established the following core elements for business growth and improved profitability under its management strategy, along with target performance indicators and reference indicators for financial guidance. Core elements for business growth and improved profitability: selection and concentration of the business portfolio; strengthening the overwhelming position in the endoscopy business; focusing on and expanding the therapeutic devices business; and leading the next-generation minimally invasive treatment market. Target performance indicators and reference indicators for financial guidance: Performance indicator — fiscal year ending March 2023 operating margin: 20% or higher. Reference indicators for financial guidance — fiscal year ending March 2023 free cash flow growth rate: 20% or higher (compound annual growth rate from the fiscal year ending March 2020); ROIC: 20% or higher; EPS growth rate: 25% or higher (compound annual growth rate from the fiscal year ending March 2020). *Levels after adjustment for special factors.」
In its medium- to long-term management strategy announced in November 2019, the Company identified concentration of its business portfolio, a focus on endoscopy and therapeutic devices, and leadership in the next-generation minimally invasive treatment market as growth drivers, and for the first time specified targets including an operating margin of 20% or higher and ROIC of 20% or higher for the fiscal year ending March 2023.